Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
Type:
Grant
Filed:
November 15, 2007
Date of Patent:
March 8, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Ulrike Fuhrmann, Anja Schmidt, Arwed Cleve, Orlin Petrov, Gunnar Garke, Stefan Pruehs, Margarete Brudny-Kloeppel, Antje Rottmann, Rainer Hasselmann, Marcus Schultze-Mosgau, Carsten Moeller
Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
Type:
Grant
Filed:
November 3, 2005
Date of Patent:
March 8, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
Abstract: The present invention relates to 2-substituted thiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof
Type:
Grant
Filed:
December 9, 2008
Date of Patent:
March 1, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Ulrich Bothe, Arne Von Bonin, Duy Nguyen, Ulf Bömer, Judith Guenther
Abstract: The invention relates to multiply substituted tetrahydronaphthalene derivatives of the formula (Ia) to processes for preparing them and to their use as antiinflammatory agents.
Type:
Grant
Filed:
March 14, 2007
Date of Patent:
February 1, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Markus Berger, Hartmut Rehwinkel, Heike Schäcke, Stefan Bäurle, Norbert Schmees
Abstract: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
February 1, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Kai Licha, Michael Schirner, Axel Vater, Sonja Vollmer
Abstract: The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.
Type:
Grant
Filed:
June 28, 2005
Date of Patent:
February 1, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Josef Stadlwieser, Thomas Baer, Thomas Maier, Thomas Beckers, Thomas Ciossek, Armin Zuelch, Ulrich Graedler
Abstract: The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C2-C4 alkyl alcohol, an active ingredient and a polymer matrix. The invention also relates to the use of a carboxylic acid diester as a transdermal permation enhancer for an active ingredient in a pharmaceutical composition in the form of a hydrogel, whereby the composition comprises a polymer matrix and a C2-C4 alkyl alcohol. The invention also relates to a sweat-resistant composition in the form of a hydrogel, which comprises an acrylic polymer in combination with a cellulose derivative.
Abstract: Method for hormone replacement therapy, in which at least in the established postmenopause a daily unit with at least one hormonal component, namely with at least estrogen (E) and/or at least one gestagen (G) is administered permanently and continuously every day, characterized in that in at least one ingestion period preceding the permanent administration of hormone daily units is provided an ingestion pause (P), in which either no daily units or placebos or daily units with a much lower estrogen and/or gestagen content than during the permanent administration of hormone daily units in the established postmenopause and during the ingestion phase(s) of the preceding ingestion period are administered, as well as administration form for hormone therapy.
Abstract: The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily dose units are administered in a method of prophylaxis and/or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated.
Type:
Application
Filed:
September 20, 2010
Publication date:
January 13, 2011
Applicant:
Bayer Schering Pharma AG
Inventors:
Christian Seitz, Annemarie Wasserfall, Holger Zimmermann
Abstract: The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.
Type:
Grant
Filed:
June 13, 2008
Date of Patent:
January 4, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Duy Nguyen, Arne von Bonin, Michael Haerter, Hartmut Schirok, Anne Mengel, Martina Schaefer, Oliver von Ahsen
Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.
Type:
Application
Filed:
August 30, 2010
Publication date:
December 23, 2010
Applicant:
Bayer Schering Pharma AG
Inventors:
Timo Flessner, Frank-Gerhard Böss, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Maria-Van Kampen, Franz-Josef Van der Staay
Abstract: This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.
Type:
Grant
Filed:
September 10, 2008
Date of Patent:
December 14, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Matthias Friebe, Peter Muschick, Andreas Huth
Abstract: The present invention describes the novel 18-methyl-19-norandrost-4-ene 17,17-spiro ethers of the general formula I in which Z is an oxygen atom, two hydrogen atoms, a group ?NOR or ?NNHSO2R, where R is a hydrogen atom or a straight- or branched-chain alkyl group having 1 to 4 or 3 to 4 carbon atoms, R4 is a hydrogen atom, a halogen atom or a trifluoromethyl group, and R6 and/or R7 may have ? or ? configuration, and R6 and R7 are independently of one another a hydrogen atom or a straight- or branched-chain alkyl group having 1 to 4 or 3 to 4 carbon atoms or a straight- or branched-chain alkenyl group having 2 to 4 or 3 to 4 carbon atoms or a saturated cycloalkyl group having 3 to 5 carbon atoms or together are a methylene group or a double bond. The novel compounds have progestational and antimineralocorticoid activity.
Type:
Grant
Filed:
June 28, 2007
Date of Patent:
December 7, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Rolf Bohlmann, Joachim Kuhnke, Jan Huebner, Norbert Gallus, Frederik Menges, Steffen Borden, Hans-Peter Muhn, Katja Prelle
Abstract: The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
Type:
Grant
Filed:
June 12, 2007
Date of Patent:
December 7, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Ulf Boemer
Abstract: The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.
Type:
Grant
Filed:
January 23, 2006
Date of Patent:
November 30, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Wolfgang Schwede, Hans Briem, Hermann Kuenzer, Manfred Husemann, Georg Kettschau, Martina Schaefer, Antonius Ter Laak, Karl-Heinz Thierauch, Stuart James Ince
Abstract: The 17?-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity.
Type:
Application
Filed:
June 12, 2008
Publication date:
November 18, 2010
Applicant:
BAYER SCHERING PHARMA AG
Inventors:
Joachim Kuhnke, Jan Huebner, Rolf Bohlmann, Thomas Frenzel, Ulrich Klar, Frederik Menges, Sven Ring, Steffen Borden, Hans Peter Muhn, Katja Prelle
Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
Type:
Application
Filed:
November 19, 2009
Publication date:
November 18, 2010
Applicant:
BAYER SCHERING PHARMA AG
Inventors:
Matthias FRIEBE, Heribert Schmitt-Willich, Mathias Berndt, Ludger Dinkelborg, Norman Koglin, Keith Graham
Abstract: The invention relates to substituted aminopyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
Type:
Grant
Filed:
June 12, 2007
Date of Patent:
November 2, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Wolfgang Schwede, Antonius M. Laak Ter
Abstract: The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as drugs.
Type:
Grant
Filed:
December 21, 2006
Date of Patent:
November 2, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Ulrich Lücking, Duy Nguyen, Arne Von Bonin, Oliver Von Ahsen, Martin Krüger, Hans Briem, Georg Kettschau, Olaf Prien, Anne Mengel, Krolikiewicz Konrad, Ulf Boemer, Ulrich Bothe, Ingo Hartung
Abstract: This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
January 18, 2008
Date of Patent:
October 26, 2010
Assignee:
Bayer Schering Pharma AG
Inventors:
Jean-Michel Vernier, Andreas Maderna, Yung-hyo Koh, Zhi Hong